Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Debt / NOTE 1.250% 9/1
-
Market price (% of par)
-
87.97%
-
Total 13F principal
-
$423,204,030
-
Principal change
-
-$526,971,984
-
Total reported market value
-
$373,473,256
-
Number of holders
-
30
-
Value change
-
-$445,467,137
-
Number of buys
-
12
-
Number of sells
-
39
Institutional Holders of SAREPTA THERAPEUTICS INC - NOTE 1.250% 9/1 as of Q3 2025
As of 30 Sep 2025,
SAREPTA THERAPEUTICS INC - NOTE 1.250% 9/1 was held by
30 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$423,204,030
in principal (par value) of the bond.
The largest 10 bondholders included
TUDOR INVESTMENT CORP ET AL, Balyasny Asset Management L.P., Linden Advisors LP, HIGHBRIDGE CAPITAL MANAGEMENT LLC, OAKTREE CAPITAL MANAGEMENT LP, D. E. Shaw & Co., Inc., DG Capital Management, LLC, Calamos Advisors LLC, Davidson Kempner Capital Management LP, and AGF MANAGEMENT LTD.
This page lists
30
institutional bondholders reporting positions
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.